Agilent Technologies, Inc.

AI-generated fair value estimate for this company.

Method: 10-year two-stage unlevered FCF DCF: $1.3B normalized annual FCF base (slightly above TTM $1.27B); 7% FCF growth years 1-5; 4.5% years 6-10; 8% discount rate; 3% terminal growth; $2.39B net debt; 281.93M shares outstanding.

Reasoning: Agilent is a stable, diversified life-sciences and diagnostics instruments/services company with recurring consumables and service revenue and moderate cyclicality, making a standard DCF on normalized unlevered FCF appropriate; growth assumptions reflect mid-single-digit organic growth plus services-mix margin expansion.